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Chapter 8c  
Successful self-initiated intermittent symptom-based vemurafenib treatment 
for metastatic melanoma
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, 
the Netherlands





Single observations by clinicians can lead to major breakthroughs, and some 
foresee even a renaissance period for clinical medicine 1. In this context, we 
would like to share a clinical observation underscoring a preclinical finding.
Daily administration of the BRAF inhibitor vemurafenib leads to tumor 
shrinkage in over 90% of the patients with a mutation in the BRAF gene. These 
effects are however short lived, with for these patients a median progression-
free survival of 5.3 months 2. Therefore, mechanisms responsible for BRAF 
inhibitor resistance development receive much attention. The effect of vari-
ous dosing schemes was studied in a human melanoma xenograft mouse 
model 3. Lethal vemurafenib resistance developed within 100 days in mice on 
daily dosing, while no resistance was seen after 200 days with an on-and-off 
schedule. Intermittent vemurafenib dosing has not yet been studied in clini-
cal trials. 
Case report
Interestingly, we describe a 76-year-old female patient who used vemurafenib intermit-
tently on her own initiative. She presented with cerebral, osseous, pulmonary and lymph 
node melanoma metastases, harboring a V600E mutation in the BRAF gene. She only had 
complaints from a painful lymph node metastasis in her right groin which disappeared 
within 2 days after initiation of vemurafenib (Figure 1A). However, she experienced dys-
pepsia, myalgia, itching and fatigue even at a 50% dose reduction, which she judged unac-
ceptable. In absence of tumor-related symptoms, she therefore discontinued treatment. 
Thereafter, she monitored the inguinal lesion by palpation and intermittently took vemu-
rafenib at progression. Radiological response measurement after 2 months showed near-
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complete remission of the brain metastases (Figure 1B), and partial remission of the other 
metastases. The serum S-100B level decreased from 0.65 µg/L at baseline to 0.04 µg/L at 
2 months and decreased further to < 0.02 µg/L at 4 months. She experienced an ongoing 
intra- and extracranial response for ~11 month, both radiological as by a persisting S-100B 
level < 0.02 μg/L, thereby exceeding the median PFS reported in trials. Overall, she took 
208 vemurafenib tablets over 49 days during this period. The cost of this treatment was 
€8,330, while the projected cost of standard treatment would have been over €106,000.
Figure 1: Radiologic response assessment.  
(A) CT slice at baseline of the right-sided inguinal lymph node metastasis, which the patient used to monitor 
her tumor response. (B) CT slice of the same lesion after 2 months treatment with on-and-off vemurafenib. (C) 
CT slice prior to vemurafenib, with an example of a brain metastasis responding to intermittent vemurafenib. 
(D) MRI slice of the same area 2 months after intermittent vemurafenib treatment.
Discussion
Two other patients, a 78-year-old and an 88-year-old male, also underwent the symptom-
based intermittent approach with vemurafenib. They both had palpable metastases on 
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occurred. The 78-year-old male had a V600R mutation in BRAF and was treated for 5 
months. The 88-year-old male was treated for 11 months and had a V600E mutation in 
BRAF. A case study supporting our hypothesis reported that patients who progressed dur-
ing BRAF inhibition after an initial good response can experience objective tumor regres-
sion again at rechallange with BRAF inhibition after a treatment-free interval (a so-called 
‘BRAF-holiday’) 4.
These cases illustrate that intermittent vemurafenib dosing is feasible and can relieve 
disease-related symptoms with an acceptable toxicity profile.
Interestingly, a phase II trial comparing intermittent sunitinib treatment versus a con-
tinuous dosing schedule in patients with advanced renal cell carcinoma showed a median 
time to tumor progression of 9.9 months for intermittent treatment and 7.1 months for 
continuous dosing (p = 0.090). Overall survival – 23.1 versus 23.5 months – was similar, 
but the intermittent group had a significantly superior outcome for time to deterioration 5.
In view of the above results, a prospective randomized clinical trial including an inter-
mittent dosing schedule of vemurafenib in BRAF mutation positive metastatic melanoma 
patients is worth considering. The 4-weeks on, 2-weeks off model, reflecting the preclini-
cal setting, would be an option 3. However, even intermittent symptom-based BRAF in-
hibitor treatment is also worth considering.
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